| Assessment Status | Rapid Review Complete |
| HTA ID | - |
| Drug | Argipressin acetate |
| Brand | Embesin® |
| Indication | For the treatment of moderate-to-severe atopic dermatitis in adults aged 18 years and older who are candidates for systemic therapy. |
| Assessment Process | |
| Rapid review commissioned | 16/09/2019 |
| Rapid review completed | 11/10/2019 |
| Rapid review outcome | A full HTA is not recommended. The NCPE recommends that argipressin acetate (Embesin®) not be considered for reimbursement at the submitted price*. |
The HSE has approved reimbursement following confidential price negotiations, March 2020.
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.
